Connor Clark & Lunn Investment Management Ltd. Buys Shares of 186,372 Merit Medical Systems, Inc. $MMSI

Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Merit Medical Systems, Inc. (NASDAQ:MMSI) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 186,372 shares of the medical instruments supplier’s stock, valued at approximately $12,923,000. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.31% of Merit Medical Systems as of its most recent filing with the SEC.

Other hedge funds have also recently modified their holdings of the company. Kilter Group LLC bought a new position in shares of Merit Medical Systems during the second quarter valued at approximately $25,000. Los Angeles Capital Management LLC purchased a new position in Merit Medical Systems during the fourth quarter valued at approximately $25,000. Torren Management LLC bought a new position in Merit Medical Systems in the fourth quarter worth approximately $38,000. Covestor Ltd lifted its holdings in Merit Medical Systems by 252.6% during the fourth quarter. Covestor Ltd now owns 469 shares of the medical instruments supplier’s stock worth $41,000 after buying an additional 336 shares during the period. Finally, Danske Bank A S purchased a new stake in Merit Medical Systems during the third quarter worth $42,000. Hedge funds and other institutional investors own 99.66% of the company’s stock.

Merit Medical Systems Stock Performance

Shares of Merit Medical Systems stock opened at $91.09 on Wednesday. The firm has a market capitalization of $5.44 billion, a P/E ratio of 37.64, a PEG ratio of 2.25 and a beta of 0.49. The company has a quick ratio of 2.79, a current ratio of 4.20 and a debt-to-equity ratio of 0.44. The company has a 50 day moving average price of $78.35 and a 200 day moving average price of $72.66. Merit Medical Systems, Inc. has a 52 week low of $59.74 and a 52 week high of $94.75.

Merit Medical Systems (NASDAQ:MMSI) last released its earnings results on Thursday, July 30th. The medical instruments supplier reported $1.19 earnings per share for the quarter, topping the consensus estimate of $0.96 by $0.23. Merit Medical Systems had a net margin of 9.22% and a return on equity of 13.75%. The company had revenue of $418.84 million for the quarter, compared to the consensus estimate of $405.25 million. During the same quarter in the previous year, the firm earned $1.01 EPS. Merit Medical Systems’s revenue was up 9.5% compared to the same quarter last year. Merit Medical Systems has set its FY 2026 guidance at 4.250-4.350 EPS. Sell-side analysts expect that Merit Medical Systems, Inc. will post 3.84 EPS for the current year.

Key Headlines Impacting Merit Medical Systems

Here are the key news stories impacting Merit Medical Systems this week:

• Positive Sentiment: Broad upward revisions to earnings forecasts: Zacks Research increased its FY2026 EPS estimate to $3.73 from $3.57, FY2027 to $4.01 from $3.82, and FY2028 to $4.32 from $4.12. Estimates were also raised for Q2 2027, Q3 2027, Q1 2028 and Q2 2028, suggesting improving expectations for Merit Medical’s earnings trajectory.
• Positive Sentiment: Growth initiatives are strengthening the investment case: New product launches, acquisitions and a broader portfolio of therapeutic medical products are supporting stronger growth and improving the company’s business mix. Recent quarterly results also showed revenue growth and an EPS beat, while the company raised its 2026 outlook. Should You Buy MMSI as Growth Improves but Valuation Stays Elevated?
• Neutral Sentiment: Short-interest data provides no meaningful signal: Reported short interest was zero shares both on August 10 and August 25, with a zero-day days-to-cover ratio. The reported “increase” is mathematically invalid, so the data does not indicate either meaningful short covering or rising bearish positioning.
• Negative Sentiment: Valuation and risk remain concerns: MMSI’s recent rally has left the stock trading at a premium valuation, increasing the need for continued earnings delivery. Analysts also cited tariff exposure and execution risks related to launches and acquisitions as potential headwinds. Can MMSI Sustain Its 22.2% Gain in the Past Month as Growth Improves?

Wall Street Analyst Weigh In

Several brokerages have issued reports on MMSI. JPMorgan Chase & Co. increased their target price on Merit Medical Systems from $77.00 to $95.00 and gave the company an “overweight” rating in a research report on Friday, July 31st. Raymond James Financial reissued an “outperform” rating and issued a $100.00 price target on shares of Merit Medical Systems in a research report on Friday, July 31st. Robert W. Baird set a $98.00 price objective on Merit Medical Systems in a research note on Friday, July 31st. Barrington Research set a $114.00 price objective on Merit Medical Systems in a research report on Friday, July 31st. Finally, Weiss Ratings upgraded Merit Medical Systems from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, August 18th. Eight analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $100.00.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.